21 March 2013

Molecular Interactions in Drug Discovery

Organised by:

SCI's Young Chemists Panel

University of Cambridge

Registration Closed

This event is no longer available for registration.

Synopsis

The area of structure-based drug design is focused on achieving stabilising and selective interactions between the ligand and the protein binding site. An understanding of how interactions behave in 3D and their relative energetics is therefore highly beneficial when assessing potential candidate molecules.

This one day event has been developed to address the area of molecular interactions and will provide the participants with a solid understanding of the various types of common interaction and how they are relevant in drug discovery. Lectures will be delivered by leading experts in the field, and topics will include the preferred geometries and energetics of interactions (such as hydrogen-bonds, aromatic interactions and halogen bonds) as well as bioisosterism and how to evaluate whether an observed interaction is important or not.

Attendees

The event is aimed primarily at early career medicinal chemists working within a pharmaceutical research environment, but may well be attractive to later career scientists interested in learning more about molecular interactions.

Programme

Event Day

Event Section

10:30: Registration and refreshments
10:50: Welcome and introduction
11:00: Keynote lecture Thinking about molecular interactions in drug discovery Dr Martin Stahl, Hoffman-La Roche
12:00: Protein interactions with fluorine and other halogens Dr Anna Vulpetti, Novartis
12:30: Lunch and exhibition
13:30: Keynote lecture The molecular recognition toolbox Prof Chris Hunter, University of Sheffield
14:30: Bioisosterism in drug discovery Dr Nathan Brown, Institute of Cancer Research
15:00: Refreshments
15:30: Experiment and theory in the study of intermolecular interactions Dr Frank Allen, Cambridge Crystallographic Data Centre
16:00: Protein-ligand molecular interaction using X-ray crystallography in fragment to lead progression Dr Gordon Saxty, Astex Therapeutics
16:30: Toward solid form design through understanding intermolecular interactions Dr Robert Docherty, Pfizer Global R&D
17:00: Closing remarks
17:10: Wine reception

Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

Venue and Contact

University of Cambridge

Pfizer Lecture Theatre, University of Cambridge, UK
Please click here for a location map.

SCI Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Fees

Earlybird fees - before 8 February 2013
GB£75 . . . . . . . . . .SCI Member
GB£25. . . . . . . . . . SCI Student
GB£100 . . . . . . . . .Non Member

Standard fees - after 8 February 2013
GB£90 . . . . . . . . . .SCI Member
GB£30 .. . . . . . . . . SCI Student
GB£120 . . . . . . . . .Non Member

Become an SCI Member and save on this and future events

See Membership Options

Booking Process/Deadlines

Booking terms and conditions

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Additional Info

Organising Committee

Pete Wood, Cambridge Crystallographic Data Centre
John Caldwell, Institute of Cancer Research
Will Farnaby, Takeda
Jamie Scott, AstraZeneca
Tom Sheppard, University College London